Discovery and multi-parametric optimization of a high-affinity antibody against interleukin-25 with neutralizing activity in a mouse model of skin inflammation.
antibody engineering
interleukin-25
psoriasis
skin inflammation
Journal
Antibody therapeutics
ISSN: 2516-4236
Titre abrégé: Antib Ther
Pays: United States
ID NLM: 101730822
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
06
07
2022
revised:
31
08
2022
accepted:
18
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Interleukin (IL)25 has been implicated in tissue homeostasis at barrier surfaces and the initiation of type two inflammatory signaling in response to infection and cell injury across multiple organs. We sought to discover and engineer a high affinity neutralizing antibody and evaluate the antibody functional activity In this study, we generated a novel anti-IL25 antibody (22C7) and investigated the antibody's therapeutic potential for targeting IL25 in inflammation. A novel anti-IL25 antibody (22C7) was generated with equivalent The generation of 22C7, an anti-IL25 antibody with efficacy in a preclinical model of skin inflammation, raises the therapeutic potential for 22C7 use in the spectrum of IL25-mediated diseases.
Sections du résumé
Background
UNASSIGNED
Interleukin (IL)25 has been implicated in tissue homeostasis at barrier surfaces and the initiation of type two inflammatory signaling in response to infection and cell injury across multiple organs. We sought to discover and engineer a high affinity neutralizing antibody and evaluate the antibody functional activity
Methods
UNASSIGNED
In this study, we generated a novel anti-IL25 antibody (22C7) and investigated the antibody's therapeutic potential for targeting IL25 in inflammation.
Results
UNASSIGNED
A novel anti-IL25 antibody (22C7) was generated with equivalent
Conclusions
UNASSIGNED
The generation of 22C7, an anti-IL25 antibody with efficacy in a preclinical model of skin inflammation, raises the therapeutic potential for 22C7 use in the spectrum of IL25-mediated diseases.
Identifiants
pubmed: 36299415
doi: 10.1093/abt/tbac022
pii: tbac022
pmc: PMC9590316
doi:
Types de publication
Journal Article
Langues
eng
Pagination
258-267Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Antibody Therapeutics. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Références
Vaccine. 1998 Nov;16(19):1880-4
pubmed: 9795396
Nat Rev Drug Discov. 2022 Feb;21(2):89
pubmed: 35027692
J Immunol. 2007 Apr 1;178(7):4557-66
pubmed: 17372014
MAbs. 2018 Feb/Mar;10(2):244-255
pubmed: 29271699
Commun Biol. 2022 May 4;5(1):415
pubmed: 35508632
J Biol Chem. 2001 Jan 12;276(2):1660-4
pubmed: 11058597
Curr Opin Pulm Med. 2020 Jan;26(1):69-76
pubmed: 31408015
Immunity. 2001 Dec;15(6):985-95
pubmed: 11754819
Immunity. 2018 Apr 17;48(4):787-798.e4
pubmed: 29653697
Front Immunol. 2021 May 28;12:691559
pubmed: 34122457
J Allergy Clin Immunol. 2021 Jul;148(1):40-52
pubmed: 33485651
J Immunol. 2013 Sep 15;191(6):3337-46
pubmed: 23945140
J Exp Med. 2006 Apr 17;203(4):1105-16
pubmed: 16606668
J Gastroenterol. 2012 Nov;47(11):1198-211
pubmed: 22539101
Diabetes Metab Syndr Obes. 2021 Dec 21;14:4875-4887
pubmed: 34992396
J Cell Biol. 2010 Nov 15;191(4):771-81
pubmed: 21059848
Life Sci Alliance. 2020 Feb 21;3(4):
pubmed: 32086318
J Allergy Clin Immunol. 2007 Dec;120(6):1324-31
pubmed: 17889290
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):944-949
pubmed: 28096333
J Invest Dermatol. 2019 Aug;139(8):1732-1742.e17
pubmed: 30738055
Immunity. 2019 Apr 16;50(4):892-906
pubmed: 30995505
J Exp Med. 2020 Jan 6;217(1):
pubmed: 31727784